Healthcare industry

Pharmaceutical research and life sciences profit from unique biosensor technology - 18/09/2015

Biametrics GmbH concludes financing round with 3.1 Million Euro

Biametrics GmbH today announced the completion of their most recent financing round with €3.1 Million. Partners of the A Series Investment were LBBW Venture GmbH, MBG Mittelständische Beteiligungsgesellschaft BW, and KfW Bankengruppe. Together with seed investors HTGF and Seedfonds BW, they are aiming to accelerate the expansion of Biametrics’ bioanalytical business activities to an international level. The fresh capital will facilitate the…

Article - 15/06/2015

Centre for Personalised Medicine in Tübingen - developing tailor-made treatments for patients

Since January 2015, Tübingen has been home to a Centre for Personalised Medicine (ZPM). Twenty-three institutes and hospitals have joined forces to improve diagnosis of disease and develop individualised treatments for patients with a variety of diseases. In parallel, the centre also develops new diagnostic strategies. This means, for example, that data derived from the analysis of the entire genetic material of cells, proteins and metabolic…

The latest articles, press releases and dossiers on diagnostics in Baden-Württemberg

Baden-Württemberg is currently home to 188 biotechnology companies. In addition to dedicated biotechnology companies, this also includes bioinformatics, diagnostics and analytics companies that use modern biotechnology methods or focus on biotechnological production.

Baden-Württemberg is Germany’s largest pharma location. In addition to industry giants such as Roche, GlaxoSmithKline and Boehringer Ingelheim, Baden-Württemberg is home to a large number of small- and medium-sized pharmaceutical companies and biotech companies with pharmaceutical research and development.

Medical technology is indispensible for human health and contributes a great deal to improving the quality of our lives. The field of medical technology covers many areas. These range from simple disposable products and consumables such as dressing materials and other clinical supplies, to IT-related telemedicine, homecare and eHealth systems as well as high-technology and innovative robotics, imaging, diagnostics and life-support systems. 842…

Article - 23/03/2015

cytena GmbH facilitates the separation of single cells

cytena GmbH, a start-up company which was spun out from the Department of Microscystems Engineering (IMTEK) at the University of Freiburg in 2014, has developed a device that enables single cells to be deposited safely and gently using a single-cell printer called cy-Clone. Once processed, the cells can be used to study tumour heterogeneity and to create clonal cell lines for producing antibodies.

Article - 26/01/2015

A biomarker as indicator for the likelihood of developing aggressive prostate cancer

Overexpression of the protein BAZ2A, which leads to alterations in epigenetic patterns, increases the malignant properties of tumour cells, including their mobility and their ability to form metastases. The findings of a team of researchers from Heidelberg, Zurich and Hamburg may have led to the discovery of an urgently needed prognostic biomarker that would make it possible to differentiate aggressive prostate cancer from the less malignant…

Article - 26/01/2015

Pooling efforts against infectious diseases in Germany

Over 150 scientists at various locations throughout Germany work together as part of the German Centre for Infection Research (DZIF). The centre focuses on the development of new diagnostic, preventive and therapeutic methods for treating infectious diseases. Scientists from the University and University Hospital of Tübingen and the Max Planck Institute for Developmental Biology are also part of the project. The researchers from Tübingen are…

Article - 19/01/2015

Kay Gottschalk and the physics of cells

You learn a great deal about the physical aspects of cells when you talk to Prof. Dr. Kay-E. Gottschalk. For example, their ability to react as solid and liquid, to adapt their environment to suit themselves and to exert and respond to forces. The 42-year-old has great respect for the smallest of living units, i.e. cells, which he calls smart composite materials. Working on the boundaries of medicine, biology, chemistry and physics, Gottschalk…

Press release - 08/01/2015

Biotech-Cluster Rhine-Neckar (BioRN) leads InnoLife consortium to success

BioRN is a member of the consortium InnoLife, which has won the call for the Knowledge and Innovation Community (KIC) Healthy Living and Active Ageing (EIT Health) of the European Institute for Innovation and Technology (EIT). With a grant volume of up to 700 million euros and a total project volume of more than 2 billion euros, this is one of the largest publicly funded initiatives in the health sector worldwide.

Article - 22/12/2014

The immune system – both weak and overreactive in the absence of CTLA4

The ability to recognise a pathogen and combat it effectively is certainly one of the most complex and sophisticated processes the human body has evolved. People with an immunodeficiency or autoimmune disease may have a genetic defect in one of the genes involved in the immune response. Working with immunologists from London scientists Desire Schubert and Prof. Dr. Bodo Grimbacher from the Centre for Chronic Immunodeficiency CCI at the Freiburg…

Article - 28/11/2014

Martin Plenio - turning Ulm’s quantum biology into a technology forge

Quantum biology has the potential to become the next big research coup. Professor Martin Plenio, 46, director of the Institute of Theoretical Physics at Ulm University and one of the world’s leading quantum technologists, is right at the forefront. He has been Alexander von Humboldt Professor since 2009, and holds a part-time professorship at Imperial College London, where he was formerly chair of quantum physics.

Press release - 26/11/2014

Curetis Closes EUR 14.5 Million Extension of Series B Financing

Curetis AG wins new investors QIAGEN and LSP-HEF, committing EUR 7 million. Hence Curetis is well financed into 2017. Curetis AG, a developer of next-level molecular diagnostic solutions, today announced it has closed a EUR 14.5 million extension of its Series B financing round, which was originally led by HBM Partners in April 2013.

Article - 20/10/2014

QIAGEN Lake Constance – pocket-sized laboratories for the efficient identification of pathogens

Quick, simple and decentralized – this is how QIAGEN Lake Constance GmbH envisages diagnostics applications in the future. The Stockach-based QIAGEN subsidiary develops test systems for point-of-need diagnostics, i.e. tests that can be carried out in close proximity to the sample collection point, for example in GP surgeries. They enable the rapid identification of pathogens, and as a result the timely initiation of suitable treatment.

Article - 13/10/2014

Personalised cancer therapy based on microRNA analysis

microRNAs are not just required for the regulation of gene expression, their expression signatures also allow conclusions to be drawn on the type and progression of cancer. Sensovation AG is therefore working with partners from industry and clinical research to develop an automated microRNA analysis platform that can detect and evaluate microRNA signatures faster than has previously been possible. The system is designed to make it easier to…

While there are specific regulations in Germany for the reimbursement of medicines, funding for molecular diagnostics products is complex and virtually non-existent. There is hardly any medical insurance cover for medical devices, which therefore tend to be sold on the open market. The question therefore arises as to how a reasonable price can be determined for innovative diagnostic methods and tools. In the second part of the interview conducted…

Article - 29/09/2014

myPOLS Biotec UG - made-to-measure enzymes for diagnostics and research

The company myPOLS Biotec UG, a spin-off from the University of Konstanz, specializes in services involving DNA and RNA polymerases and creates artificial enzymes by evolution in test tubes. These next-generation polymerases can be used for many research and diagnostics applications. myPOLS Biotec’s polymerases are promising enzymes for future applications with the potential to make the detection of pathogens and DNA analysis faster and easier.

Article - 08/09/2014

Molecular effects of traumatic stress

After a traumatic experience, people often suffer not only mental, but also physical effects. Dr. María Moreno-Villanueva from the University of Konstanz has investigated the molecular effects of traumatic stress in people and has found a higher than normal number of DNA strand breaks. In the worst cases this can lead to diseases such as cancer. However, her study also shows that successful psychotherapy can reverse DNA damage. Her findings will…

Article - 11/08/2014

dsl-Labor: developing PCR tests for medical diagnostics

PCR has become a common application in medical diagnostics, in areas ranging from the detection of microbes to genetic testing. The demand for new tests is huge, given that there is a seemingly endless list of applications for which PCR can be used. dsl-Labor für Molekulargenetische Diagnostik specialises in the development of PCR tests and also gives advice and training to medical laboratory personnel. Veterinarians are among the company’s major…

Article - 21/07/2014

Predicting the efficiency of cancer drugs using mathematical models

A research consortium was established at the Stuttgart Research Center Systems Biology SRCSB at the University of Stuttgart in January 2013 with the goal of establishing models that help predict the action of targeted therapeutics. The scientists combine molecular biology experiments with complex mathematical models in order to achieve a holistic understanding of disease and therapy.

Article - 14/07/2014

Andreas Marx – “Chemical Biology” of DNA polymerases

Whether inside the cell or in molecular biology laboratories, the synthesis of DNA would not be possible without DNA polymerases. The regulation and application of this versatile enzyme family is the subject of research carried out by Prof. Dr. Andreas Marx at the University of Konstanz in Southern Germany. In addition to basic research into naturally occurring DNA polymerases, Marx deals with the development of novel polymerases that can be used…

Article - 30/06/2014

Targeting epigenetic DNA modifications for the diagnosis of cancer

Epigenetic DNA modifications have been shown to play a role in carcinogenesis and are therefore a promising target for the early detection of cancer. Dr. Daniel Summerer and his research group at the University of Konstanz have developed a method that enables the direct and site-specific identification of epigenetic changes. The method represents a new approach in the field of epigenetic analysis as well as a major step towards simpler cancer…

Article - 28/04/2014

Sciomics: antibody microarrays and their broad range of applications

Sciomics GmbH is a start-up biotech from Heidelberg with a special focus on protein microarrays. Sciomics produces complex, high-density antibody microarrays for cancer-relevant proteins and offers services for medical research, diagnostics and the industry, including biomarker screening, the verification of biomarker candidates, the analysis and localization of drug targets and their signalling pathways as well as the characterization of…